Abstract
Despite medical advancements, morbidity and mortality rates associated with acute coronary syndrome (ACS) remain high, particularly one year after the acute event. Recent studies have shown that PCSK9 inhibitors therapy can significantly reduce plasma low-density lipoprotein cholesterol (LDL-C) levels and major adverse cardiovascular events in post-ACS patients through plaque modification. This review describes the current clinical benefits of PCSK9 inhibitors therapy early after ACS in reducing LDL-C levels and the risk of major adverse cardiovascular events. Clinical trials such as EVOPACS, ODYSSEY OUTCOMES, PACMAN-AMI, and V-INCEPTION are discussed. In conclusion, early implementation of PCSK9 inhibitors in addition to high-intensity statins in ACS appears to be a safe and effective approach to achieving LDL-C treatment goals and reducing the burden of atherosclerotic disease.